DEFA14A: Alkermes to Acquire Avadel Pharmaceuticals

Alkermes plc announced its intent to acquire Avadel Pharmaceuticals plc, aiming to expand its neuroscience leadership and sleep disorder portfolio.

Summary

• Alkermes plc intends to acquire Avadel Pharmaceuticals plc, as announced on October 22, 2025, via a Transaction Agreement.
• The acquisition will be implemented through a court-sanctioned scheme of arrangement under Irish law, or potentially a takeover offer under specific circumstances.
• Alkermes aims to integrate Avadel's scientific excellence, strong commercial infrastructure, and innovative approach with its existing neuroscience leadership.
• The combined entity is expected to expand treatment options and close gaps for patients suffering from sleep disorders.
• Alkermes is currently developing alixorexton, an orexin 2 receptor agonist, for narcolepsy and idiopathic hypersomnia.
• The acquisition is anticipated to leverage combined investigational pipelines to drive significant growth.
• A smooth integration process is prioritized, with a focus on preserving Avadel's culture and capabilities.

Sentiment

Score: 9

Explanation: The filing communicates a highly positive and strategic acquisition, emphasizing complementary strengths, growth opportunities, and patient benefits, with a strong focus on smooth integration and cultural preservation.

Positives

• Alkermes views Avadel's scientific excellence, strong commercial infrastructure, and innovative approach as highly aligned with its strategic vision and corporate values.
• The acquisition presents an unprecedented opportunity to expand treatment options and address unmet needs for patients with sleep disorders.
• The combination of investigational pipelines is expected to drive significant growth for the merged entity.
• Alkermes' established leadership in neuroscience is anticipated to strengthen Avadel's market position and development capabilities.
• Alkermes has committed to preserving Avadel's culture and capabilities during the integration process.

Risks

• The ability of the parties to consummate the acquisition in a timely manner or at all.
• The satisfaction (or waiver) of conditions to the acquisition, including shareholder and required regulatory approvals.
• Potential delays in consummating the acquisition.
• The ability of the Company and Alkermes to timely and successfully achieve the anticipated benefits of the acquisition.
• The impact of health pandemics on the parties' respective businesses and the actions taken in response.
• The occurrence of any event, change, or circumstance that could lead to the termination of the Transaction Agreement.
• The effect of the announcement or pendency of the acquisition on business relationships, operating results, and general business of both companies.
• Costs related to the acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or their directors/officers related to the Transaction Agreement or the acquisition.

Future Outlook

Alkermes expects to welcome Avadel to its team early next year. The combined teams, infrastructure, and investigational pipelines are anticipated to expand options, close treatment gaps for sleep disorder patients, and drive significant growth.

Management Comments

• "This marks an important step forward, not just for our two organizations, but for the broader sleep disorder community." Richard Pops, CEO of Alkermes.
• "From our earliest conversations, it was clear that your team's scientific excellence, strong commercial infrastructure and innovative approach aligned closely with our strategic vision and corporate values." Richard Pops, CEO of Alkermes.
• "We believe that together, our teams, infrastructure and expertise in sleep disorders along with our combined investigational pipelines, provide an unprecedented opportunity to expand options, close treatment gaps and reach more patients living with sleep disorders and drive significant growth." Richard Pops, CEO of Alkermes.
• "We see this as more than just an acquisition. It is the beginning of a collaboration built on mutual respect, complementary strengths and a joint commitment to translating cutting-edge science into transformative outcomes." Richard Pops, CEO of Alkermes.
• "Our priority will be to preserve the culture and capabilities that make your team exceptional while identifying opportunities to amplify our collective impact." Richard Pops, CEO of Alkermes.

Industry Context

The acquisition positions Alkermes to strengthen its leadership in neuroscience, particularly in the sleep disorder market. By combining Avadel's commercial infrastructure and expertise with Alkermes' existing neuroscience pipeline, including alixorexton for narcolepsy and idiopathic hypersomnia, the combined entity aims to address unmet patient needs and compete more effectively in the specialized sleep therapeutics sector.

Stakeholder Impact

• Shareholders: Will be required to vote on the acquisition and will receive detailed information via a definitive proxy statement.
• Employees: Alkermes' CEO expressed excitement to welcome Avadel employees, with a stated priority to preserve Avadel's culture and capabilities.
• Patients/Sleep Disorder Community: Expected to benefit from expanded treatment options and closed treatment gaps due to the combined expertise and investigational pipelines.

Next Steps

• Filing of preliminary and definitive Proxy Statement (including the scheme document) with the SEC.
• Sending the definitive Proxy Statement to Company shareholders for voting.
• Company shareholder meetings to approve the acquisition.
• Satisfaction of conditions to consummation, including required regulatory approvals.
• Smooth integration of Avadel into Alkermes, with a focus on preserving culture and capabilities.
• Alkermes expects to welcome Avadel to its team early next year.

Key Dates

Keywords

Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, Sleep Disorders, Narcolepsy, Idiopathic Hypersomnia, Neuroscience, Pharmaceuticals, Biotechnology, SEC Filing, Scheme of Arrangement